Drug Profile
Pegylated darbepoetin alfa biosimilar - Merck & Co.
Alternative Names: Erythropoietin biosimilar - Merck & Co.; MK-2578; Recombinant PEG-erythropoietin biosimilar - Merck & Co.Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlycoFi
- Developer Merck & Co
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 28 Aug 2013 Discontinued - Phase-II for Anaemia in Italy (SC)
- 28 Aug 2013 Discontinued - Phase-II for Anaemia in USA (SC)
- 01 May 2010 Discontinued - Phase-II for Anaemia in Bulgaria (SC)